NHP T-Cell-Dependent Antibody Response (TDAR) Models

The T-cell-dependent antibody response (TDAR) is a gold standard assay for assessing the impact of drug candidates on immune competence during preclinical development. This functional immune assay evaluates the integrity of multiple immune processes, including antigen uptake and presentation, T cell help, B cell activation, and antibody production. Regulatory agencies recommend TDAR as a first-choice immune function test for immunotoxicity evaluation of new chemical entities. HKeyBio offers a well-validated NHP TDAR model using keyhole limpet hemocyanin (KLH), a highly immunogenic protein that elicits robust T-cell-dependent antibody responses. This model provides critical immunotoxicity and immunopharmacology data to support IND-enabling studies.

Quantity:
Availability:





Inquire Add to Basket

Product Description

Key Features & Benefits

Regulatory gold standard – TDAR is recommended by FDA, EMA, and ICH S8 as a first-choice immune function test for immunotoxicity assessment.

Comprehensive immune assessment Quantifiable endpoints – KLH-specific IgM and IgG titers; B cell phenotyping (percentage and absolute counts); primary and secondary response kinetics.

IND-ready data packages – Studies can be conducted in accordance with GLP principles for regulatory submissions.

Technical Data & Validation

Representative data from our KLH Induced NHP TDAR model:

KLH Induced NHP TDAR Model

442b58e5ff8ee8e4a18dd8f49a4db946

Applications

• Immunotoxicity assessment of small molecules, biologics, and immunomodulators

• IND-enabling studies requiring immune function evaluation (ICH S8 compliance)

• Mechanism of action studies for immunosuppressive or immunostimulatory drugs

• Vaccine adjuvant evaluation

• Biomarker discovery for immune competence

Model Specifications

Parameter	Specification
Species	Cynomolgus macaque (Macaca fascicularis)
Induction method	Immunization with keyhole limpet hemocyanin (KLH), typically with adjuvant, intramuscular or subcutaneous administration
Study duration	4–8 weeks (primary and secondary response assessment)
Key endpoints	KLH-specific IgM (day 7-14), KLH-specific IgG (day 14-28), B cell phenotyping (percentage and absolute counts), optional: T cell subsets, cytokine profiling
Data package	Raw data, analysis reports, flow cytometry files, bioinformatics (optional)

❓ Frequently Asked Questions

Q 1: What is the NHP TDAR model and what is it used for?

A1: TDAR refers to T-Cell-Dependent Antibody Response. Our KLH-induced NHP TDAR model is a gold-standard preclinical assay to evaluate drug-induced immunotoxicity and assess overall immune competence.

Q2: What is the principle of the KLH induced NHP TDAR model?

A2: Keyhole limpet hemocyanin (KLH) is a highly immunogenic protein. It triggers typical T-cell-dependent immune reactions, which can effectively detect the immunosuppressive effects of candidate drugs.

Q3: What detection indicators are included in this model?

A3: We test serum anti-KLH IgM and IgG levels, as well as the percentage and absolute count of B cells in peripheral blood for comprehensive immune function analysis.

Q4: What is the modeling cycle and key time points?

A4: KLH immunization is performed on Day 0. Sample collection and all relevant detections are completed by Day 21.

Q5: What are the advantages of using NHP for TDAR assessment?

A5: Non-human primates share high similarity with humans in immune systems. The model delivers reliable and predictive data, which is ideal for immunotoxicity evaluation of novel drugs